Feasibility of Incorporating Frailty Testing into Standard Assessment of Heart Transplant Candidacy

Goldwater, Deena; Ventigan, N.; Shih, Liang‐Chun; Jaladanki, Suraj; Junio, G.; Shukman, M.; Moore, M.; Biniwale, Reshma; Ardehali, A.; Nsair, Ali; Schaenman, Joanna

doi:10.1016/j.healun.2020.01.1094

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, the Frailty Heart Group recommended a modified PFP [ 32 ] in HT evaluation as it is easy to perform and has been validated in patients with advanced HF [ 26 , 33 ]. While evidence remains sparse, observational studies have shown frailty can be incorporated into the HT evaluation process and is an independent risk factor for mortality and prolonged hospitalization following HT [ 34 , 35 ••, 36 ]. Evidence from the kidney transplant literature reflects similar adverse short- and long-term post-transplant outcomes for frail candidates [ 27 , 37 – 39 ].…”

Section: Pre-transplant Considerations For Older Adultsmentioning

confidence: 99%

Heart Transplant in Older Adults

Rushakoff

Kransdorf

2022

Curr Transpl Rep

View full text Add to dashboard Cite

Purpose of Review Older adults with end-stage heart failure may be candidates for heart transplantation (HT) and changing guidelines and institutional policies have increased the availability of HT for septuagenarians. This review explores historical, pre-HT evaluation, and post-HT outcomes for older adult HT recipients. Recent Findings Rates of HT in older adults have increased in the past decade and more than 800 septuagenarians have undergone HT. Older adult HT recipients have similar survival, rehospitalization, and graft failure rates when compared to younger patients despite additional comorbidities and higher risk donors. Summary HT is feasible in carefully selected older adults. As the number of older adults who are considered for HT increases, additional research into population-specific assessment tools will be needed. Furthermore, age-related immune changes warrant population-specific studies on immunosuppressive regimens.

show abstract